Evaluation of the Therapeutic Efficacy of Different Levothyroxine Preparations in the Treatment of Human Thyroid Disease
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
At the present time, optimal therapy for hypothyroidism requires replacement of the deficiency in thyroid hormone with synthetic levothyroxine. Precise titration of this narrow therapeutic index drug is necessary to return the patient to a chemically and clinically euthyroid state. Seven levothyroxine formulations are Food and Drug Administration (FDA)-approved and four are available to the physician. Proper dosage is established based on thyrotropin (TSH) testing and clinical evaluation. Each levothyroxine preparation must comply with FDA standards for bioavailability but may vary with respect to its dissolution and absorption properties and are not interchangeable. This equivalence testing is done on normal volunteers and requires a suprapharmacologic dose of levothyroxine in order to make the determination of bioavailability. In this review we discuss the various methods to evaluate therapeutic efficacy and bioequivalence of levothyroxine preparations in the treatment of thyroid disease. These are relevant to the physician and patient because small differences in the efficacy can produce unwanted effects of either underreplacement or overreplacement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824 · cited 1×
“Recently Canaris and colleagues 22 have observed that as many as 21% of patients receiving T 4 treatment had subclinical hyperthy-roidism (23).”
Thyroid hormone and the cardiovascular system.
Klein, I., & Ojamaa, K. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440707 · Cited by 2,300
Self-citationHak, A. E., Pols, H. A. P., Visser, T. J., Drexhage, H. A., Hofman, A., & Witteman, J. C. M. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-4-200002150-00004 · Cited by 1,336
Low Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons
Sawin, C. T., Geller, A., Wolf, P. A., Belanger, A. J., Baker, E., Bacharach, P., Wilson, P., Benjamin, E. J., & D'Agostino, R. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311901 · Cited by 1,259 · cited 5×
“These changes in serum TSH both increased and decreased, in turn, can correlate with atrial fibrillation (3).”
InfluentialLaboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Andersen, S., Pedersen, K. M., Bruun, N. H., & Laurberg, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8165 · Cited by 686
Treatment Guidelines for Patients With Hyperthyroidism and Hypothyroidism
Singer, P. A. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520340064038 · Cited by 427
Increased need for thyroxine during pregnancy in women with primary hypothyroidism
Mandel, S. J., Larsen, P. R., Seely, E. W., & Brent, G. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230204 · Cited by 360
Bioequivalence of Generic and Brand-name Levothyroxine Products in the Treatment of Hypothyroidism
Dong, B. J. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540390035032 · Cited by 185 · cited 3×
“There have been a number of bioequivalence and bioavailability studies published (6,7,32).”
Treatment of Hyperthyroid Disease
Klein, I., Becker, D. V., & Levey, G. S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00010 · Cited by 120 · cited 2×
“The signs and symptoms of hyperthyroidism and the treatment thereof are also well known (13–15).”
Self-citationHays, M. T. (1988) · Endocrine Research · doi:10.3109/07435808809032986 · Cited by 94 · cited 1×
“…tract, primary gastrointestinal pathology including sprue and celiac disease, the residual effects of hypothyroidism on gastrointestinal function and lastly, the presence of interfering substances such as a variety of food stuffs, minerals, and medications that may alter drug absorption (11,31).”
Cited by
Hypothyroidism as a Risk Factor for Cardiovascular Disease
Biondi, B., & Klein, I. (2004) · Endocrine · doi:10.1385/endo:24:1:001 · Cited by 412
Self-citationPabla, D., Akhlaghi, F., & Zia, H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.10.008 · Cited by 124
Carswell, J. M., Gordon, J. H., Popovsky, E., Hale, A., & Brown, R. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3125 · Cited by 83
“L-T4 in a fasting state (32), thereby magnifying potential differences in dissolution properties between L-T4 formulations (22).”
TSH-Based Protocol, Tablet Instability, and Absorption Effects on L-T 4 Bioequivalence
Eisenberg, M., & Distefano, J. J. (2009) · Thyroid · doi:10.1089/thy.2008.0148 · Cited by 43
Levothyroxine sodium pentahydrate tablets – formulation considerations
Kaur, N., & Suryanarayanan, R. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.08.006 · Cited by 19
Metadata
- Authors
- Klein, I., & Danzi, S.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2003-12
- Volume
- 13
- Issue
- 12
- Pages
- 1127-1132
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W2156267380
- Cited by
- 24
- References
- 11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.